VEGFA and choroidal neovascularization: Intravitreal injection of anti-VEGF agents is effective at inhibiting choroidal neovascularization (CNV) in about 40% patients, but long-term risks include potential retinal and ocular harm from loss of VEGF-beneficial effects and rare complications related to intraocular injections [3,4].